10x Genomics joined Roche Sequencing Solutions and Prognosys Biosciences to file two federal lawsuits accusing Illumina of infringing nine patents tied to spatial biology and single‑cell sequencing technologies. The plaintiffs seek injunctions, damages and a court ruling that Illumina’s recent spatial transcriptomics and single‑cell product launches infringe licensed intellectual property. Complaints, filed in the U.S. District Court for the District of Delaware, name four spatial‑biology patents and five single‑cell patents and request permanent relief. Illumina denied the claims and said it will vigorously defend itself. The litigation follows prior patent disputes in the sequencing and spatial‑omics arena and reflects intensifying IP battles as companies commercialize high‑value platforms. The cases could affect product roadmaps, licensing strategies and collaborative research access in single‑cell and spatial markets, where instrument and reagent sales form critical competitive moats. Court outcomes may reshape licensing norms and influence consolidation or defensive dealmaking across the genomics tools sector.